JP2015166379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015166379A5 JP2015166379A5 JP2015102945A JP2015102945A JP2015166379A5 JP 2015166379 A5 JP2015166379 A5 JP 2015166379A5 JP 2015102945 A JP2015102945 A JP 2015102945A JP 2015102945 A JP2015102945 A JP 2015102945A JP 2015166379 A5 JP2015166379 A5 JP 2015166379A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- unit dosage
- less
- naproxen
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 28
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 16
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 16
- 229960002009 naproxen Drugs 0.000 claims 16
- 239000002245 particle Substances 0.000 claims 14
- 239000011159 matrix material Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 5
- 238000004090 dissolution Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 5
- 239000007962 solid dispersion Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229960004977 anhydrous lactose Drugs 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229960001855 mannitol Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000009837 dry grinding Methods 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17228909P | 2009-04-24 | 2009-04-24 | |
| AU2009901746A AU2009901746A0 (en) | 2009-04-24 | A Novel Formulation of Naproxen | |
| AU2009901746 | 2009-04-24 | ||
| US61/172,289 | 2009-04-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Division JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015166379A JP2015166379A (ja) | 2015-09-24 |
| JP2015166379A5 true JP2015166379A5 (https=) | 2015-11-12 |
| JP6177275B2 JP6177275B2 (ja) | 2017-08-09 |
Family
ID=43010609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Active JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
| JP2015102945A Expired - Fee Related JP6177275B2 (ja) | 2009-04-24 | 2015-05-20 | ナプロキセンの新規製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506288A Active JP6116244B2 (ja) | 2009-04-24 | 2010-04-23 | ナプロキセンの新規製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20120148634A1 (https=) |
| EP (1) | EP2421512A4 (https=) |
| JP (2) | JP6116244B2 (https=) |
| KR (3) | KR20160135370A (https=) |
| CN (2) | CN103877030A (https=) |
| AP (1) | AP3530A (https=) |
| AU (1) | AU2010239085C1 (https=) |
| CA (1) | CA2759122A1 (https=) |
| CO (1) | CO6470806A2 (https=) |
| EA (1) | EA201171284A1 (https=) |
| IL (1) | IL215868A0 (https=) |
| MA (1) | MA33299B1 (https=) |
| MX (1) | MX344222B (https=) |
| NZ (2) | NZ595985A (https=) |
| SG (2) | SG175767A1 (https=) |
| TN (1) | TN2011000536A1 (https=) |
| UA (1) | UA111578C2 (https=) |
| WO (1) | WO2010121326A1 (https=) |
| ZA (1) | ZA201108648B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| CN102438594A (zh) | 2009-04-24 | 2012-05-02 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| WO2015179098A1 (en) | 2014-05-21 | 2015-11-26 | Integenx Inc. | Fluidic cartridge with valve mechanism |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| CN106537128B (zh) | 2014-06-09 | 2021-06-18 | 生物统计股份有限公司 | 用于测量分析物的低成本测试条和方法 |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| CN107106983B (zh) | 2014-10-22 | 2021-04-16 | 尹特根埃克斯有限公司 | 用于样品制备、处理和分析的系统和方法 |
| US10210410B2 (en) | 2014-10-22 | 2019-02-19 | Integenx Inc. | Systems and methods for biometric data collections |
| US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
| WO2017136617A1 (en) | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| CN114859028A (zh) | 2016-07-19 | 2022-08-05 | 生物统计股份有限公司 | 使用批量可校准测试条测量分析物的方法和系统 |
| JP7163015B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
| AU2018255063A1 (en) * | 2017-04-21 | 2018-11-22 | Bio-Synectics Inc. | Method for preparing active material nanoparticles using lipid as lubricant for milling |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| US11779541B2 (en) | 2019-03-26 | 2023-10-10 | Johnson & Johnson Consumer Inc. | Immediate release dosage form |
| DK4245298T3 (en) * | 2020-12-18 | 2026-03-30 | Daewoong Pharmaceutical Co Ltd | Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin |
| KR20250112022A (ko) * | 2024-01-16 | 2025-07-23 | 피투케이바이오 주식회사 | 리바록사반 흡입용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| DE60203506T2 (de) * | 2001-06-22 | 2006-02-16 | Marie Lindner | Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics |
| EP1830824B1 (en) * | 2004-12-31 | 2016-01-13 | Iceutica Pty Ltd. | Nanoparticle composition and methods for synthesis thereof |
| AU2007264418B2 (en) * | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| KR20090027734A (ko) * | 2006-07-27 | 2009-03-17 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법 |
| AP3138A (en) * | 2009-04-24 | 2015-02-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
| JP5898613B2 (ja) * | 2009-04-24 | 2016-04-06 | イシューティカ ピーティーワイ リミテッド | 生物学的活性物質の溶解プロファイルを改善するための方法 |
| US20120160944A1 (en) * | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
-
2010
- 2010-04-23 EA EA201171284A patent/EA201171284A1/ru unknown
- 2010-04-23 NZ NZ595985A patent/NZ595985A/en not_active IP Right Cessation
- 2010-04-23 SG SG2011077476A patent/SG175767A1/en unknown
- 2010-04-23 AP AP2011005991A patent/AP3530A/xx active
- 2010-04-23 AU AU2010239085A patent/AU2010239085C1/en not_active Ceased
- 2010-04-23 SG SG10201401720RA patent/SG10201401720RA/en unknown
- 2010-04-23 MA MA34386A patent/MA33299B1/fr unknown
- 2010-04-23 KR KR1020167032025A patent/KR20160135370A/ko not_active Ceased
- 2010-04-23 EP EP10766519A patent/EP2421512A4/en not_active Withdrawn
- 2010-04-23 CA CA2759122A patent/CA2759122A1/en not_active Abandoned
- 2010-04-23 KR KR1020147034848A patent/KR20150008909A/ko not_active Ceased
- 2010-04-23 NZ NZ626401A patent/NZ626401A/en not_active IP Right Cessation
- 2010-04-23 CN CN201410119438.1A patent/CN103877030A/zh active Pending
- 2010-04-23 JP JP2012506288A patent/JP6116244B2/ja active Active
- 2010-04-23 UA UAA201113810A patent/UA111578C2/uk unknown
- 2010-04-23 CN CN201080017987.8A patent/CN102438592B/zh not_active Expired - Fee Related
- 2010-04-23 MX MX2011011220A patent/MX344222B/es active IP Right Grant
- 2010-04-23 WO PCT/AU2010/000470 patent/WO2010121326A1/en not_active Ceased
- 2010-04-23 US US13/266,119 patent/US20120148634A1/en not_active Abandoned
- 2010-04-23 KR KR1020117027887A patent/KR20120104489A/ko not_active Ceased
-
2011
- 2011-10-23 IL IL215868A patent/IL215868A0/en unknown
- 2011-10-24 TN TNP2011000536A patent/TN2011000536A1/en unknown
- 2011-11-23 CO CO11160580A patent/CO6470806A2/es not_active Application Discontinuation
- 2011-11-24 ZA ZA2011/08648A patent/ZA201108648B/en unknown
-
2014
- 2014-01-21 US US14/160,463 patent/US20140200276A1/en not_active Abandoned
- 2014-11-24 US US14/552,413 patent/US20150087709A1/en not_active Abandoned
-
2015
- 2015-05-20 JP JP2015102945A patent/JP6177275B2/ja not_active Expired - Fee Related
- 2015-07-14 US US14/799,438 patent/US20150313857A1/en not_active Abandoned
-
2016
- 2016-04-07 US US15/093,667 patent/US20160220518A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015166379A5 (https=) | ||
| JP2015157851A5 (https=) | ||
| KR20100117097A (ko) | 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물 | |
| CN104546747A (zh) | 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法 | |
| CN106551912B (zh) | 一种提高难溶性药物溶出度的方法 | |
| NZ626401A (en) | A novel formulation of naproxen | |
| HRP20220332T1 (hr) | Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv | |
| EP3518928A1 (en) | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| JP6966780B2 (ja) | アセトアミノフェン製剤の製造方法 | |
| US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| CN112351772B (zh) | 颗粒尺寸不一致的原料药颗粒的处理方法 | |
| US20190314349A1 (en) | Pyridone derivative pharmaceutical composition and preparation method thereof | |
| CN101939002B (zh) | 与糖醇共微粉化的恩他卡朋药物组合物 | |
| CN103933004B (zh) | 一种来曲唑片剂及其制备方法 | |
| CN110573183A (zh) | 一种帕博西林组合物及其制备方法 | |
| CN102626410A (zh) | 一种含有罗氟司特的药物组合物 | |
| CN103142607B (zh) | 一种替吉奥胶囊制剂的制备方法 | |
| CN106913544B (zh) | 一种快速溶出的吉非替尼片剂及其制备方法 | |
| JPWO2019093434A1 (ja) | アセトアミノフェン製剤及びその製造方法 | |
| CN101623311A (zh) | 微粉化维参锌及其药物组合物 | |
| CN108721238A (zh) | 一种碳酸锂缓释片 | |
| CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
| CN103877064B (zh) | 一种非诺贝特胶囊剂及其制备工艺 | |
| WO2013130584A2 (en) | Formulation containing ws727713 | |
| JP2018177800A (ja) | プレミックス原薬の製造方法 |